The bill CS/HB 57 2025 amends Florida Statutes to regulate xylazine, a substance now classified as a controlled substance. It exempts certain FDA-approved xylazine animal drug products used according to their approved applications, while clarifying that the manufacture, importation, distribution, prescribing, or sale of xylazine for human use is not exempt. The bill introduces criminal penalties for the sale, manufacture, delivery, or possession with intent to sell xylazine, establishing a mandatory minimum term of imprisonment and creating a new offense for trafficking in xylazine, with penalties varying based on the quantity involved.

Furthermore, the bill expands the list of illegal substances by including various synthetic cannabinoids and substituted cathinones, detailing their chemical structures and potential modifications. It emphasizes the importance of the appearance of these substances, particularly when they resemble food products or are packaged attractively for minors. The bill aims to enhance law enforcement's ability to combat drug trafficking and protect public health, with an effective date set for July 1, 2025.

Statutes affected:
H 57 Filed: 893.13, 893.135
H 57 c1: 893.03, 893.13, 893.135